PresentationPresentation XPO1 is selinexor prime target: validation by mutating cysteine 528 on both XPO1 alleles using CRISPR/Cas9 genome editing PDF (1.18 MB) Read MorePresentation Selective inhibitor of nuclear export (SINE) compounds show synergistic anti-tumor activity in combination with dexamethasone in multiple myeloma PDF (2.26 MB) Read MorePresentation XPO1 is a rational target for double and triple-hit aggressive B-cell lymphomas PDF (2.93 MB) Read MorePresentation Preclinical activity in non-Hodgkin’s lymphoma of Selinexor, a selective inhibitor of nuclear export (SINE), is enhanced through combination with standard-of-care therapies PDF (923.36 KB) Read MorePresentation F-box protein fbxl5 nuclear retention by specific inhibitors of nuclear export induces snail ubiquitination leading to reversal of EMT PDF (1.16 MB) Read MorePresentation Deconstructing protein and gene expression pathways to define the anticancer effects of XPO1 inhibition in ovarian cancer PDF (3.87 MB) Read MorePresentation Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): a report from the Pediatric Preclinical Testing Program PDF (1.33 MB) Read MorePresentation Single cell longitudinal studies reveal cell cycle specific effects of selective inhibitors of nuclear export (SINE) PDF (1.23 MB) Read MorePresentation Preclinical activity of selinexor, an inhibitor of XPO1/CRM1, in sarcoma PDF (2.40 MB) Read MorePresentation Novel PAK4 allosteric modulators (PAMs) provide potential therapeutic options in human gastric cancer PDF (555.57 KB) Read More Previous 1 … 9 10 11 12 13 … 15 Next